standards > reporting guideline > DOI:10.25504/FAIRsharing.f67zb7


deprecated LINCS Pilot Phase 1 Metadata Standards: RNAi Reagents

Abbreviation: LINCS 1: RNAi Reagents


General Information
This record was deprecated on March 28, 2017 for the following reason(s): This standard was a pilot study for the LINCS 2 Nucleic Acid Reagents standard (https://biosharing.org/bsg-s000699) and as such has been superseded.

The LINCS Pilot Phase 1 metadata standards annotate reagents outside the context of the experiments in which they were used. RNA interference is a standard methodology to transiently knock down gene expression in living cells. This can be achieved using different types of small RNA molecules, including siRNA, shRNA, and miRNA. Information that is relevant to identify and describe these perturbations include probe ID, name, source/provider, target gene symbol and accession number, sequence of the probe, and modifications to the probe (e.g., chemical modification) if any are specified.



How to cite this record FAIRsharing.org: LINCS 1: RNAi Reagents; LINCS Pilot Phase 1 Metadata Standards: RNAi Reagents; DOI: https://doi.org/10.25504/FAIRsharing.f67zb7; Last edited: Feb. 22, 2018, 2:16 p.m.; Last accessed: Nov 20 2018 3:11 p.m.


This record is maintained by cchung  ORCID

Record added: May 18, 2016, 10:14 a.m.
Record updated: March 28, 2017, 7:58 p.m. by The FAIRsharing Team.

Show edit history


In Collections


Support

General

Additional Information


Tools

    No tools defined


Schemas

No XSD schemas defined


Access / Retrieve Data

Conditions of Use





Publications

No publications available



Implementing Databases (1)
Library of Integrated Network-Based Cellular Signatures Data Portal
The LINCS Data Portal provides a unified interface for searching LINCS dataset packages and reagents. LINCS data are being made openly available as a community resource through a series of data releases, so as to enable scientists to address a broad range of basic research questions and to facilitate the identification of biological targets for new disease therapies. LINCS datasets consist of assay results from cultured and primary human cells treated with bioactive small molecules, ligands such as growth factors and cytokines, or genetic perturbations. Many different assays are used to monitor cell responses, including assays measuring transcript and protein expression; cell phenotype data are captured by biochemical and imaging readouts. Assays are typically carried out on multiple cell types, and at multiple timepoints; perturbagen activity is monitored at multiple doses.

Implementing Policies

This record is not implemented by any policy.


Credit

Record Maintainer

Funds